GlassScriptPhysician profile
Thuyvy Le
NPI 1841751088
$5,273.45
in general payments reported to CMS, 2019-2025
22 companies · $1,668 in 2025
The $1,668 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2022: $824 · 2023: $1,022 · 2024: $1,522 · 2025: $1,668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,211.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,477.34 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $1,209.60 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $505.49 | 2022-2023 | Austedo, Austedo Xr |
| Amgen INC. | $354.24 | 2022-2025 | Otezla, Repatha, Otezla |
| Ibsa Pharma INC. | $282.07 | 2024-2025 | Tirosint, Licart, Flector |
| Novo Nordisk INC | $223.53 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $186.69 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Kyowa Kirin, INC. | $174.12 | 2024 | Nourianz |
| Bayer Healthcare Pharmaceuticals INC. | $151.53 | 2024-2025 | |
| Horizon Therapeutics Plc | $130.31 | 2022 | |
| Alkermes, INC. | $118.11 | 2022 | |
| Tela Bio, INC. | $103.00 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Inspire Medical Systems, INC. | $99.22 | 2023 | Inspire |
| Xeris Pharmaceuticals, INC. | $38.72 | 2025 | Gvoke Hypopen |
| Abbott Laboratories | $38.35 | 2025 | Freestyle Libre 3 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $36.10 | 2025 | Zenpep |
| Merck Sharp & Dohme LLC | $31.28 | 2025 | Gardasil 9, Capvaxive |
| Abbvie INC. | $30.36 | 2024 | |
| Pfizer INC. | $26.85 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $22.85 | 2025 | Zoryve |
| Medtronic, INC. | $20.85 | 2024 | Venaseal |
| Biotissue Holdings INC. | $12.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thuyvy Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.